Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes -: A randomized, controlled trial

被引:273
作者
Fritsche, A
Schweitzer, MA
Häring, HU
机构
[1] Univ Tubingen, Med Klin, Abt Endokrinol Stoffwechsel & Pathobiochem, D-72076 Tubingen, Germany
[2] Aventis, Frankfurt, Germany
关键词
D O I
10.7326/0003-4819-138-12-200306170-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients with type 2 diabetes are often treated with oral antidiabetic agents plus a basal insulin. Objective: To investigate the efficacy and safety of glimepiride combined with either morning or bedtime insulin glargine or bedtime neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes. Design: open-label, randomized, controlled trial. Setting: 111 centers in 13 European countries. Patients: 695 patients with type 2 diabetes who were previously treated with oral antidiabetic agents. Intervention: Randomization to treatment with morning insulin glargine, bedtime NPH insulin, or bedtime insulin glargine for 24 weeks in addition to 3 mg of glimepiride. The insulin dose was titrated by using a predefined regimen to achieve fasting blood glucose levels of 5.56 mmol/L or lower (less than or equal to100 mg/dL). Measurements: Hemoglobin A(1c) values, blood glucose levels, insulin dose, and body weight. Results: Hemoglobin A(1c) levels improved by -1.24% (two-sided 90% CI, -1,10% to -1.38%) with morning insulin glargine, by -0.96% (CI, -0.81% to -1.10%) with bedtime insulin glargine, and by -0.84% (CI, -0.69% to -0.98%) with bedtime NPH insulin. Hemoglobin A(1c) improvement was more pronounced with morning insulin glargine than with NPH insulin (0.40% [CI, 0.23% to 0.58%]; P = 0.001) or bedtime insulin glargine (0.28% [CI, 0.11% to 0.46%]; P = 0.008). Baseline to end-point fasting blood glucose levels improved similarly in all three groups. Nocturnal hypoglycemia was less frequent with morning (39 of 236 patients [17%]) and bedtime insulin glargine (52 of 227 patients [23%]) than with bedtime NPH insulin (89 of 232 patients [38%]) (P < 0.001). Conclusion: The risk for nocturnal hypoglycemia was lower with glimepiride in combination with morning and bedtime insulin glargine than with glimepiride in combination with bedtime NPH insulin in patients with type 2 diabetes. Morning insulin glargine provided better glycemic control than did bedtime insulin glargine or bedtime NPH insulin.
引用
收藏
页码:952 / 959
页数:8
相关论文
共 26 条
[1]  
[Anonymous], 1995, Diabetes, V44, P1249
[2]   The relationship between physicians' self-reported target fasting blood glucose levels and metabolic control in type 2 diabetes - The QuED Study Group - Quality of care and outcomes in type 2 diabetes [J].
Belfiglio, M ;
De Berardis, G ;
Franciosi, M ;
Cavaliere, D ;
Di Nardo, B ;
Greenfield, S ;
Kaplan, SH ;
Pellegrini, F ;
Sacco, M ;
Tognoni, G ;
Valentini, M ;
Nicolucci, A ;
Caimi, V ;
Capani, F ;
Corsi, A ;
Della Vedova, R ;
Benedetti, MM ;
Nicolucci, A ;
Taboga, C ;
Tombesi, M ;
Vespasiani, G .
DIABETES CARE, 2001, 24 (03) :423-429
[3]   Insulin analogues and their potential in the management of diabetes mellitus [J].
Bolli, GB ;
Di Marchi, RD ;
Park, GD ;
Pramming, S ;
Koivisto, VA .
DIABETOLOGIA, 1999, 42 (10) :1151-1167
[4]   Well-being and symptoms in relation to insulin therapy in type 2 diabetes [J].
de Sonnaville, JJJ ;
Devillé, W ;
Snoek, FJ ;
Wijkel, D ;
Colly, LP ;
Heine, RJ .
DIABETES CARE, 1998, 21 (06) :919-924
[5]   Hypoglycaemia and counterregulation in type 2 diabetes [J].
Gerich, JE .
LANCET, 2000, 356 (9246) :1946-1947
[6]   Insulin glargine [J].
Gillies, PS ;
Figgitt, DP ;
Lamb, HM .
DRUGS, 2000, 59 (02) :253-260
[7]   MORNING OR BEDTIME NPH INSULIN COMBINED WITH SULFONYLUREA IN TREATMENT OF NIDDM [J].
GROOP, LC ;
WIDEN, E ;
EKSTRAND, A ;
SALORANTA, C ;
FRANSSILAKALLUNKI, A ;
SCHALINJANTTI, C ;
ERIKSSON, JG .
DIABETES CARE, 1992, 15 (07) :831-834
[8]   Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction [J].
Haffner, SM ;
Lehto, S ;
Rönnemaa, T ;
Pyörälä, K ;
Laakso, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (04) :229-234
[9]  
Holman R R, 1985, Diabet Med, V2, P45
[10]   NIDDM patients' fears and hopes about insulin therapy - The basis of patient reluctance [J].
Hunt, LM ;
Valenzuela, MA ;
Pugh, JA .
DIABETES CARE, 1997, 20 (03) :292-298